Tag Archives: pharmaceutical

Posted in Medical-Education on March 4th, 2009 by Mark Hollander

Consumers Prefer To Learn About Drugs Online

epsilon

As reported in MediaPost Marketing Daily,  the results are in from marketing services firm Epsilon.

Consumers would rather learn about prescription drugs via Web sites and email than through traditional offline advertising and marketing…

While an in-person conversation still topped the list of sources for new information, Epsilon reported that receiving an email from a physician was significantly less desirarble at just 14%.   Other findings include:

Consumers who opt to receive emails from pharmaceutical companies are more likely to fill prescriptions and take read more…

Comments Off

Posted in Social Media on February 24th, 2009 by Mark Hollander

Pharma and Facebook: Connect, Attract and Promote

Silja Chouquet over at whydot pharma is an advocate of pharmaceutical companies using social media to improve patient outcomes.  She’s written a great post highlighting 3 ways pharma is using Facebook to:

Connect current and ex- employees.
Attract talent, including  student, intern and training program groups
Promote disease awareness, including examples like:
McNeil Pediatrics’ ADHD Moms (which I blogged about earlier),
Novartis’ Zometa Marcia Strassman Takes Role as Patient Advocate, and
Merck’s Gardasil Take a Step Against Cervical Cancer (by way of a comment posted by read more…

Comments Off

Posted in Buzzword Status Report on January 23rd, 2009 by Mark Hollander

Pharma has Reason to Be Afraid of Social Media Marketing

the galaxy of social media sites includes Facebook, YouTube and more

Warning letters. Off-label promotion. Adverse drug reaction reporting. These are compelling reasons why pharmaceutical, biotechnology and medical device marketers should be nervous about social media. There’s little regulatory guidance and lots of risk.

Watch out for hype

Just because “social media” is the big buzzword for Q1-2009 doesn’t mean it’s right for health care products.  Consider a recent blog post over at Adotas by respected marketer Michael Maher:

Drug firms must communicate via social networks because it’s a primary way consumers prefer to make health read more…

3 Comments

Posted in Medical-Education on July 6th, 2008 by Mark Hollander

Vyvanse Gets It Right With Patient-Ed Starter Kit

Vyvanse Starter Kit front cover

Shire’s Vyvanse™ is the newest addition to the family of medications used to treat ADHD (Attention Deficit and Hyperactivity Disorder) in children and as of April 23 adults as well.  Given that ADHD is a disorder shrouded in confusion, shame and sometimes controversy, there is a demonstrated need for premium patient education.

We reviewed the “Vyvanse™ : Child’s Starter Kit” (made available to parents by physicians) and found it to be one of the best DTC-Patient Ed pieces we’ve seen read more…

1 Comment

Posted in Social Media on March 11th, 2008 by Mark Hollander

BioPharma and Social Media: 3 Criteria For Creating Safe Marketing Strategy

The pharmaceutical industry cannot blog. That’s one takeaway I had in reading a white paper by Envision Solutions, TNS Media Intelligence/Cymfony and law firm Seyfarth Shaw, LLP. In “Making the Case for a Social Media Strategy in Healthcare” the authors draw attention to three critical risks that must always be considered:

Off-Label Promotion. Avoid marketing a product for a non-FDA approved condition. (Proposed legislation would allow BioPharma greater latitude in this area)
Adverse Event Reporting. The obligation to report read more…

Comments Off

Posted in 80/20 Rule on March 2nd, 2007 by Mark Hollander

Pareto Plus Pharma Equals Profit

Pharmaceutical Executive guest columnist Sander Flaum has written a wonderful sketch of the 80/20 rule entitled “Leadership: Pareto’s Principle” It’s a quick read and for those of us who work in Sales and Marketing is particularly relevant:

“…a recent study of 25,000 salespeople in 160 industries, which concluded that 55 percent of them were ill-suited to salesmanship; half of the remainder sold “the wrong thing in the wrong place.” Conclusion: 20 percent produced 80 percent of the sales.”

Mr. Flaum suggests that read more…

Comments Off